Carregant...
Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab
BACKGROUND: Antiangiogenic therapy with bevacizumab has failed to provide substantial gains in overall survival. Epithelial membrane protein 2 (EMP2) is a cell surface protein that has been previously shown to be expressed in glioblastoma, correlate with poor survival, and regulate neoangiogenesis i...
Guardat en:
| Publicat a: | Neurooncol Adv |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7542982/ https://ncbi.nlm.nih.gov/pubmed/33063013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa112 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|